Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

"Erdheim-Chester disease" - Google News
Connecting Caregivers with Resources and Support - KAAL
Connecting Caregivers with Resources and Support  KAAL

Each year, more than 43 million people provide unpaid care to an adult or child in the U.S. according to the "National Center on Caregiving". The physical ...


Wednesday, November 28, 2018 3:00:00 AM

18F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker - Journal of Nuclear Medicine
18F-FDG PET/CT in Erdheim–Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker  Journal of Nuclear Medicine

+ Author Affiliations. 1Department of Radiology, Mayo Clinic, Rochester, Minnesota. 2Department of Immunology, Mayo Clinic, Rochester, Minnesota; and.


Tuesday, May 01, 2018 3:00:00 AM

CNS Abnormalities Common in Erdheim-Chester Disease - Neurology Advisor
CNS Abnormalities Common in Erdheim-Chester Disease  Neurology Advisor

Patients with Erdheim-Chester disease (ECD) are at risk for a variety of central nervous system (CNS) abnormalities, and brain and spine magnetic resonance ...


Friday, February 23, 2018 3:00:00 AM

First-Ever FDA Approval for Erdheim-Chester Disease - MedPage Today
First-Ever FDA Approval for Erdheim-Chester Disease  MedPage Today

WASHINGTON -- The FDA today granted a first-ever approval for treatment of the rare blood cancer Erdheim-Chester Disease (ECD), the agency announced.


Monday, November 06, 2017 3:00:00 AM

NanoString Technologies Highlights Advances in Precision Oncology at the 60th Annual Meeting of the American Society of Hematology - Nasdaq
NanoString Technologies Highlights Advances in Precision Oncology at the 60th Annual Meeting of the American Society of Hematology  Nasdaq

40+ Abstracts Highlight the Value of the nCounter Platform in Hematology & Immuno-oncology, Including Thirteen that Demonstrate the Potential Utility of the ...


Thursday, November 29, 2018 5:00:00 AM

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation - Rare Disease Report
Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation  Rare Disease Report

The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 ...


Sunday, August 06, 2017 3:00:00 AM

Leader of stock swindle that stole $19 million from 12,000 victims gets 3 months in prison - Hartford Courant
Leader of stock swindle that stole $19 million from 12,000 victims gets 3 months in prison  Hartford Courant

Christian Meissenn, the Suffield man who was the central figure in a criminal enterprise that stole more than $19 million from 12,000 victims through penny stock ...


Thursday, November 29, 2018 3:00:00 AM

On Rare Disease Day, experts say ‘Don’t give up’ - KING5.com
On Rare Disease Day, experts say ‘Don’t give up’  KING5.com

Rare Disease Day raises awareness of disorders that affect very few of us. A Camano Island woman shares her story of fighting to save her own life.


Wednesday, February 28, 2018 3:00:00 AM

Genes associated with Erdheim-Chester disease also linked to cancer - Medical Xpress
Genes associated with Erdheim-Chester disease also linked to cancer  Medical Xpress

National Human Genome Research Institute (NHGRI) researchers have identified new genes associated with the Erdheim-Chester disease (ECD) and some ...


Friday, March 31, 2017 3:00:00 AM

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease - Cancer Network
FDA Approves Vemurafenib for Treating Erdheim-Chester Disease  Cancer Network

The FDA has expanded the approval of vemurafenib (Zelboraf) to include the treatment of Erdheim–Chester disease in adult BRAF V600–positive patients.


Thursday, November 09, 2017 3:00:00 AM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us 
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!